The Goldline Pharmaceutical initial public offering (IPO) witnessed an overwhelming response from investors, with the SME issue of the Maharashtra-based pharmaceutical products marketing firm subscribed 781.85 times overall.
The participation in the IPO was driven across all investor categories, including Institutional Investors and retail applicants. The mainboard issue saw total bids for 1,53,86,88,000 shares against 19,68,000 shares offered.
The Qualified Institutional Buyers (QIBs) were allotted 5,40,000 shares, with bids for 9,73,17,000 shares. This led to a subscription of 180.22 times.
The Non-Institutional Investors (NII) segment emerged as the biggest driver of demand, subscribing 1,227.90 times, with bids for 64,83,33,000 shares against 5,28,000 shares offered. Within this category, high-value bids (above Rs 10 lakh) saw particularly aggressive participation, subscribed over 2,011.14 times.
The Retail Individual Investors (RIIs) portion was subscribed 881.15 times, with applications for nearly 79,30,38,000 shares compared to 9,00,000 shares offered.
Steps To Check Goldline Pharmaceuticals IPO Allotment On BSE
1. Open the BSE allotment page here.
2. Under the Issue Type field, select Equity.
3. Choose 'Goldline Pharmaceuticals Limited' from the Issue Name dropdown.
4. Enter your Application Number or PAN.
5. Complete the Captcha verification.
6. Click Search to check your allotment status.
Steps To Check Goldline Pharmaceuticals IPO Allotment Status On Bigshare Services
1. Go to the Bigshare Services IPO allotment page here.
2. Select any one server to verify allotment status.
3. From the dropdown list of company names, select "Goldline Pharmaceuticals".
4. Choose an identification method, either PAN Card, Application Number or Beneficiary ID. Enter the corresponding details.
5. Enter the corresponding details and click Search to check your allotment status.
The shares of Goldline Pharmaceutical are set to debut on the BSE SME platform, with the tentative listing date scheduled for May 19.
Goldline Pharmaceutical IPO Latest GMP
According to InvestorGain, Goldline Pharmaceutical SME IPO's latest GMP stands at Rs 15 on May 15. Based on the upper end of the price band of Rs 43, the estimated listing price stands at Rs 58 per share, implying a potential gain of 34.88% on listing.
The grey market premium for Goldline Pharmaceutical IPO was as high as Rs 25 when the issue opened for Day 3 subscription, indicating a possible listing gain of more than 55%.
Goldline Pharmaceutical IPO Details
Goldline Pharmaceutical IPO was a book-built issue of Rs 11.61 crore. The IPO consists entirely of a fresh issue of 27 lakh shares. The price band was fixed at Rs 41 to Rs 43 per share. The minimum lot size for retail investors was 3,000 shares. Retail investors could apply for at least two lots, or 6,000 shares, taking the minimum investment amount to Rs 2.58 lakh. For HNI investors, the minimum application size was three lots, or 9,000 shares, amounting to Rs 3.87 lakh.
Cumulative Capital Pvt. Ltd. is the book-running lead manager for the issue, while Bigshare Services Pvt. Ltd. is the registrar. Nirman Share Brokers Pvt. Ltd. is the market maker for the IPO.
About Goldline Pharmaceutical
Goldline Pharmaceutical operates across multiple therapeutic segments. The company's portfolio is divided into five segments. Goldline Pharma has 42 products focused on specialities such as orthopaedics, ENT, gastroenterology, neurology, urology and surgery.
Goldline Cardinal offers 54 products for physicians, diabetologists, endocrinologists and cardiologists. Goldline Aayushman includes 18 products catering to paediatricians, neonatologists and child specialists. Goldline InLife has 22 products aimed at intensivists, critical care consultants and super-speciality surgeons. Goldline Wellness includes 10 products focused on supportive care in cancer treatment.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
